[{"address1": "Nihonbashi Mitsui Tower", "address2": "Reception12F 1-1 Nihonbashi-Muromachi 2-chome", "city": "Chuo", "zip": "103-8324", "country": "Japan", "phone": "81 3 3281 6611", "fax": "81 3 3281 6607", "website": "https://www.chugai-pharm.co.jp", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Osamu  Okuda", "age": 61, "title": "President, CEO & Chairman", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1606959, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iwaaki  Taniguchi", "age": 57, "title": "Executive VP, Head of Finance Supervisory Division, CFO & Director", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Toshiya  Sasai", "title": "Executive of Investor Relations Group & Corporate Communications Department", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Masayoshi  Higuchi", "title": "VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept.", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Junichi  Takano", "title": "Head of Marketing & Sales Division", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shinji  Hidaka", "title": "Executive Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Junichi  Ebihara", "title": "Executive Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yoshiaki  Ohashi", "age": 64, "title": "Senior VP & Full-time Audit Supervisory Board Member", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tetsuya  Yamaguchi", "title": "Executive VP & Head of PHC Solution Unit", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshiyuki  Yano", "title": "Executive Vice President", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 7, "compensationRisk": 1, "shareHolderRightsRisk": 2, "overallRisk": 5, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.chugai-pharm.co.jp/hc/ss/english/ir/index.html", "maxAge": 86400, "priceHint": 2, "open": 46.26, "dayLow": 46.26, "dayHigh": 46.26, "regularMarketOpen": 46.26, "regularMarketDayLow": 46.26, "regularMarketDayHigh": 46.26, "dividendRate": 0.64, "dividendYield": 0.0149, "exDividendDate": 1751241600, "payoutRatio": 0.4164, "trailingPE": 27.692308, "forwardPE": 28.051949, "volume": 288, "regularMarketVolume": 288, "averageVolume": 7426, "averageVolume10days": 5900, "averageDailyVolume10Day": 5900, "bid": 43.04, "ask": 46.4, "bidSize": 40000, "askSize": 40000, "marketCap": 75324383232, "fiftyTwoWeekLow": 29.75, "fiftyTwoWeekHigh": 52.22, "fiftyDayAverage": 42.72374, "twoHundredDayAverage": 40.56335, "trailingAnnualDividendYield": "NaN", "currency": "USD", "sharesOutstanding": 1645529984, "heldPercentInsiders": 0.59911996, "heldPercentInstitutions": 0.18722999, "impliedSharesOutstanding": 1743619968, "bookValue": 1094.714, "priceToBook": 0.03946236, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "trailingEps": 1.56, "forwardEps": 1.54, "lastSplitFactor": "3:1", "lastSplitDate": 1593388800, "52WeekChange": 0.23217344, "SandP52WeekChange": 0.19995654, "lastDividendValue": 0.255, "lastDividendDate": 1719446400, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CHGCF", "underlyingSymbol": "CHGCF", "shortName": "CHUGAI PHARMACEUTICAL CO", "longName": "Chugai Pharmaceutical Co., Ltd.", "firstTradeDateEpochUtc": 1344000600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "0db76804-27c0-3882-bffb-8f19fb3eeeda", "messageBoardId": "finmb_685347", "gmtOffSetMilliseconds": -18000000, "currentPrice": 43.2, "recommendationKey": "none", "financialCurrency": "JPY", "trailingPegRatio": 4.0579, "__fetch_time": "2025-02-08"}]